Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended access program for bardoxolone methyl in pulmonary hypertension
2016-004365-16Phase 3Terminated
- Sponsor
- Reata Pharmaceuticals
- Start
- Mar 2017
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bardoxolone methyl in pulmonary hypertension (PH), sponsored by Reata Pharmaceuticals. Primary endpoints: Safety and tolerability of bardoxolone methyl (adverse events), Change in physical examination findings and 4 more. Started Mar 2017; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2016-004365-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004365-16.